Akebia slightly lowered Auryxia net product revenue guidance to $170M-$175M for 2023 from $175M-$180M due to an unfavorable impact from market dynamics, volume and payor mix.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKBA:
- Biotech Alert: Searches spiking for these stocks today
- Akebia upgraded to Buy from Neutral at H.C. Wainwright
- Akebia reaffirms 2023 Auryxia net product revenue guidance of $175M-$180M
- Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Akebia reports Q2 EPS (6c) vs. 15c last year
